The Oesterreich lab is working to further the understanding of development and progression of breast cancer, in order to improve clinical management of breast cancer patients, with the ultimate goal to improve outcome.  We focus on three areas of research: i) resistance to hormonal therapy, including further understanding of the estrogen receptor ii) development and progression of invasive lobular breast cancer (ILC), the second most common histological subtype of breast cancer, and iii) drivers of metastases in breast cancer.

5 ways to find out which is the best drug for my erectile dysfunction problem:  Kamagra in Australia

OESTERREICH LAB PUBLICATIONS

2018

  1. Jia S, Miedel MT, Ngo M, Hessenius R, Chen N, Wang P, Bahreini A, Li Z, Ding Z, Shun TY, Zuckerman DM, Taylor DL, Puhalla SL, Lee AV, Oesterreich S, Stern AM. Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes. Oncology. 2018 Jan 6;94(3):176-189.[Epub ahead of print] PubMed PMID: 29306943.
  2. Li Z, Levine KM, Bahreini A, Wang P, Chu D, Park BH, Oesterreich S, Lee AV. Upregulation of IRS1 Enhances IGF1 Response in Y537S and D538G ESR1 Mutant Breast Cancer Cells. Nolvadex in Australia for breast cancer therapy. Endocrinology. 2018 Jan 1;159(1):285-296. PubMed PMID: 29029116.
  3. Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali S, Ross J, Leyland-Jones B, Young B, Williams C, Park B, Tsai M, Haley B, Peguero J, Callahan RD, Sachelarie I, Cho J, Atkinson JM, Bahreini A, Nagle AM, Puhalla SL,  Watters RJ, Erdogan-Yildirim Z, Cao L, Oesterreich S, Mathew A, Lucas PC, Davidson NE, Brufsky AM, Frampton GM, Stephens PJ, Chmielecki J, Lee AV. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast  cancer. Ann Oncol. 2018 Jan 19. doi: 10.1093/annonc/mdy025. [Epub ahead of print] PubMed PMID: 29360925.
  4. Oesterreich S, Lucas PC, McAuliffe PF, Bruno TC, Vignali DAA. Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer. J Natl Cancer Inst. 2018 Feb 20. doi: 10.1093/jnci/djy014. [Epub ahead of print] PMID: 29471462

Contacts

204 Craft Avenue
Pittsburgh, PA 15213

Tel: 412-641-7724
Fax: 412-641-2468

Main Menu